Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine --- Advisory Committee on Immunization Practices, 2011

Morbidity and Mortality Weekly Report

Volumn 60, Issue 20, 2011, Pages 661-663

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; AGED; ANIMAL; ARTICLE; ASIA; CERCOPITHECUS; CLINICAL TRIAL (TOPIC); HEALTH CARE PERSONNEL; HUMAN; IMMUNIZATION; IMMUNOLOGY; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; LABORATORY; MIDDLE AGED; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; UNITED STATES; VERO CELL;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, NEUTRALIZING; ASIA; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CERCOPITHECUS AETHIOPS; CLINICAL TRIALS AS TOPIC; ENCEPHALITIS VIRUSES, JAPANESE; ENCEPHALITIS, JAPANESE; GUIDELINES AS TOPIC; HEALTH PERSONNEL; HUMANS; IMMUNIZATION, SECONDARY; JAPANESE ENCEPHALITIS VACCINES; LABORATORIES; MIDDLE AGED; UNITED STATES; VACCINES, INACTIVATED; VERO CELLS;

EID: 79958287508     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. CDC. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(No. RR-1).
2. Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis 2002;35:183-8.
3. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines. Vaccine 2005;23:5205-11.
4. Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008;26:4382-6.
5. European Medicines Agency. Annex 1: summary of product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000963/WC500037287.pdf. Accessed May 22, 2011.
6. Dubischar-Kastner K. Data supporting the use of a booster dose of Ixiaro. Presentation to Advisory Committee on Immunization Practices (ACIP), February 23, 2011, Atlanta, GA. Available at http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-feb11/03-2-jev-booster.pdf. Accessed May 22, 2011.
7. Dubischar-Kastner K, Eder S, Buerger V, et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine Ixiaro, IC51. Vaccine 2010;28:5197-202.
8. Schuller E, Klade CS, Heinz FX, et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 2008;26:6151-6.
9. Eder S, Dubischar-Kastner K, Firbas C, et al. Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine Ixiaro, IC51. Vaccine 2011;29:2607-12.